Scroll To Top
Search by Speciality

8th Emirates Diabetes & Endocrine Congress (EDEC 2018)

Dubai World Trade Centre | Dubai, UAE
From 325 to 550 USD
Event Preview
This event
is Finished
Title: 8th Emirates Diabetes & Endocrine Congress (EDEC 2018)
Specialty: Internal Medicine
Dates: From Mar, 1, 2018 to Mar, 3, 2018
Location: Dubai, UAE
Type: Course
Registration Cost: From 325 to 550 USD
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for DUBAI, Uae.
General Info
Event Venue:

Dubai World Trade Centre

DUBAI, UAE Visit the Venue to read more
Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

Dear colleagues and friends,

AhlanWaSahlan! Marhaba and Welcome once again!

I am proud to announce that the 7th edition of the Emirates Diabetes & Endocrine Congress will take place again from 16 - 18 February 2017 at the Dubai World Trade Centre. Looking back to 2016, the congress experienced a record number of attendees reaching 2,887 delegates! This just proves that the need for education and training in the field of diabetes and endocrinology is every more important.

Every year, we gather in Dubai to discuss the ever increasing burden of diabetes in our societies and the various options as care providers we have to tackle this disease. We at the Emirates Diabetes Society know first-hand that education is the key to building a foundation on which we can reduce this burden and we as the medical community are in the forefront of this education transmission.

We will continue to provide the region's premier platform to update our participants on the recent advances in the ever-changing field of diabetes and endocrine diseases.

The global fight against diabetes and endocrine diseases continues to strengthen because of the on-going collaboration of our communities, and I have the highest hopes and confidence in that it will continue to do so!

I look forward to another successful meeting, and I welcome all new and returning participants to the congress!

Dr. Abdulrazzaq Ali Al Madani

President, Emirates Diabetes Society

President, Emirates Diabetes &Endocrine Congress 2017

Registration Needs updating Register Now
General Info:

Registered Physicians, Residents, Nurses, Medical Students & Interns are entitled to attend all scientific sessions, the exhibition, as well as receive the congress material.

All registrants are required to pre register.

For administrative and preparatory reasons, pre registration & name changes are possible until 14th February 2018 12:00 hrs (GMT+ 4). From this date onwards, we advise you to register and pay the applicable fee on-site during congress registration hours commencing on 1st March 2018.

** For administrative purpose, a copy of your certificate is required as a proof in order to avail the registration fee for a resident, medical student or nurse.



Registration Cost
Early Registration

Late Registration From: 2017-10-17 To: 0--
On site Registration

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts


The 8th Emirates Diabetes & Endocrine Congress 2018 will take place at the Dubai World Trade Centre.

Whether it's the key conferences and exhibitions that make up the annual calendar, Dubai World Trade Centre's (DWTC) wide selection of venues, extensive services, award-winning hospitality or world class facilities management, aim to surpass expectations every time.The Dubai World Trade Centre connects people, products and ideas from around the globe through the year-round calendar of international trade fairs, blockbuster consumer shows and prestigious international conferences.

DWTC has played a pivotal role in the growth of international trade for the Middle East, ever since the inauguration in 1979. Then, it was through the landmark 39-storey Sheikh Rashid Tower, today the region's largest purpose-built complex for events and exhibitions.

The epicentre for business tourism in the region, DWTC powers the MICE sector through its size, resources, diversity of calendar and scale of events. As well as connecting people through the events they host, they play a major role within Dubai's economy, attracting revenue for the city's sights, restaurants and hotels. Each year, DWTC events create more than 25,000 jobs or 36,000 including ancillary sectors that benefit from our events.

DWTC continue to be driven by their role, not just in Dubai's past but also in its future and to challenge and to create even better experiences for all their clients, exhibitors and visitors.

For more information, please visit

Scientific Content Up to Date
Submission Info


The Emirates Diabetes Society is proud to announce the 8th Emirates Diabetes & Endocrine Congress. The Scientific Committee invites individuals to submit abstracts for oral and poster presentations.

Research Reports

Abstracts must contain original scientific data collected by the author(s). All reports must be based on work that has already been completed. No studies "in progress" will be accepted. Any established research design or method may be used.

Submission of Poster Presentations


Language: All abstracts are to be written in English. The Scientific Committee reserves the right to edit abstracts where the English structure makes comprehension difficult.

Submission: All abstracts must be submitted via the abstract portal on the website. This should be limited to a maximum of 500 words and should include the following:

Title of abstract

Names and contact details of author(s) {organization, city /country, email, phone numbers, fax numbers and mailing address}. Please indicate the name of the presenter/s clearly and provide a 3 line biography of the author/s with your abstract.

The abstract must include the following headings clearly: Purpose, Relevance, Participants, Methods, Analysis, Results, and Conclusions. (Please provide evidence of ethical approval and funding acknowledgements if any)

You will be notified of receipt of your abstract by email. If you do not receive an email within two weeks of submittal or have any additional queries please contact, email:

Important Dates:

30 November 2017 - Early bird registration deadline

10 November 2018 - Last date for submission of abstract

Selection Criteria

Abstracts will be evaluated through a blind review process and scored based upon the following criteria:

Relevance to the conference topics

Relevance / interest to the physiotherapy community

Scientific merit of research ( including methodological rigor and contemporary contribution to knowledge)

Quality, clarity and completeness of abstracts

Poster Presentation Specifications:

Information should be summarized using brief written statements, graphic materials, such as photographs, charts, graphs, and diagrams mounted on standard size poster boards (84 cm X 110 cm), pins or other mounting materials will be supplied.

Authors must prepare all posters beforehand in a form enabling easy mounting.

Poster orientation must be portrait. Clear labels must be used for each section of the poster. Text should be of sufficient size for easy reading at a distance of 1.5 meter (between 16-20 points).

Title must be displayed clearly at the top of the poster and should include the names of the author(s) and the institution(s) of origin

Display and Presentation:

Poster presenters are responsible for mounting and taking down their poster during the conference.

Designated times for poster presentations will be incorporated into the conference.

Poster presenters should be available to discuss their posters with the conference participants during these periods and during the coffee breaks.

Depending upon the number of poster presentations accepted, posters may be on display throughout the conference

Terms and Conditions

The Scientific Committee reserves the right to make the final decision about the abstract acceptance and its scheduling into the program based on topics and time constraints.

The language of the conference is English.

All abstracts must be prepared using the poster presentation submission guidelines.

Each presenter may submit a maximum of two (2) abstracts.

Each abstract submission must indicate if the material was published or presented in any prior conferences or if it received any awards.

All presenters must register to attend the conference within a maximum of 1 week of acceptance of the abstract and be present at the time of the conference.

A certificate of appreciation will be given to all the presenters to honor their presentation.

Presenters must not use the session as a marketing opportunity for products\equipment

Fee or payment of travel /living expenses or registration charges will not be provided.

Abstract submission deadline 2017-11-30
Sponsors Exhibitors
General Info

MCI Middle East

United Arab Emirates

Tel: +971 4 311 6300

Fax: +971 4 311 6301

Email : 

Sponsors / Supporters

Diamond Sponsor

MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc.,Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical companydedicated to putting patients first. Established in 1891, MSD discovers, develops,manufactures and markets vaccines and medicines to address unmet medical needs.MSD has been present for over than 30 years in the GULF region. MSD GULF operatesthroughout offices based in the UAE, Kuwait, Bahrain, Qatar & Oman and ranksamongst the leading pharmaceutical companies throughout the GULF region. Throughits local distributors, MSD GULF provides innovative medications in several diseaseentities. These include products for Anti- Infectives, Cardiovascular, Asthma & Allergy,Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility,Ophthalmic, and Anesthesia in addition to several specialized Vaccines.

Platinum Sponsors

Diabetes is a lifelong challenge for people living with it.

That is why Lilly Diabetes provides a wide range of therapies connected with consistent support that allow care to be tailored as needs change.

We know that even with the best of medicines, it can be hard for people with diabetes to reach and stay at goal. Since we introduced the first commercially available insulin in 1923, the needs of people with diabetes have continually inspired us to innovate and introduce pathways to better outcomes.

We believe that when it comes to helping people achieve those outcomes, efficacy and safety are critical. We also understand that simplicity and ease of use are just as important.

For a person with diabetes, achieving a goal can be hard. Understanding and taking a medicine should not be.

Founded in Darmstadt, Germany, in 1668 by Friedrich Jacob Merck, we are the world's oldest pharmaceutical and chemical company. Today, the Merck family remains the majority owner of the company. Over the course of nearly 350 years, we have become a truly global company.

Our approximately 50,000 people work in 66 countries and are united by their passion for new ideas, the possibilities of technology, and the potential to make a difference in the world.

In healthcare we help to create, improve and prolong life - continuously working to make a lasting difference to patients' lives. Our portfolio includes medicines to treat cancer, multiple sclerosis, infertility, growth disorders, cardiovascular diseases, diabetes and thyroid disorders. We develop high-quality products that protect every member of your family so that they can enjoy healthier, happier lives every day We are known as Merck internationally. In the United States and Canada we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

For more information please visit

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit

Novartis is on Twitter. Sign up to follow @Novartis at
For Novartis multimedia content, please visit For questions about the site or required registration, please contact:

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.

NN Story: Behind the Novo Nordisk we know today lies an exciting story that goes back 90 years. It began with the two small Danish companies Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium founded in 1923 and 1925, respectively. The two companies started the production of the revolutionary new drug insulin that had just been discovered by two Canadian scientists. A 1935 export advertisement for insulin Novo

Building on the past - looking to the future 
Since the earliest days, both Nordisk and Novo had focus on the development of products to benefit people with diabetes. Competing intensely with one another, the companies developed into two of the best in their field. When at last they decided to merge in 1989, they created Novo Nordisk. A company that has been expanding rapidly ever since with leading positions within diabetes care, haemophilia care, growth hormone therapy and hormone replacement therapy.

Today the Novo Nordisk Way shows responsibility to patients, employees, communities and investors. We will in the future continue to build on the legacy left by the founders of Novo Nordisk and do whatever it takes to change diabetes. Our history tells us it can be done.

At Sanofi Diabetes, our priorities are focused on the needs of people with diabetes around the world. With a century of experience in this area, we strive to help people manage the complex challenge of diabetes by delivering a range of innovative, personalized solutions integrated across diagnostics, therapies, devices and services. Because we understand the daily impact of diabetes and our patients' aspirations, we know how to improve their quality of life. We want people to live 'beyond' diabetes, to achieve aspirations and to make the most of everyday!

Our principal medicinal products in the field of diabetes are: Lantus® (insulin glargine), a long-acting human insulin analogue. Lantus® is available is more than 120 countries worldwide. Apidra® (insulin glulisine) a rapid-acting human insulin analogue. Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist. Amaryl® (glimepiride), a sulfonylurea-class hypoglycemic. Furthermore, other diabetes treatments are currently in clinical development.

Servier is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular-, metabolic-, neurologic-, psychiatric-, bone- and joint diseases as well as cancer.

Organising Agency

MCI Middle East

United Arab Emirates

Tel: +971 4 311 6300

Fax: +971 4 311 6301

Email : 

Official Event Webpage
Event map
Revelant Events